Literature DB >> 6517559

Changes in the pharmacokinetics of ciprofloxacin and fecal flora during administration of a 7-day course to human volunteers.

W Brumfitt, I Franklin, D Grady, J M Hamilton-Miller, A Iliffe.   

Abstract

Twelve male subjects, aged 19 to 40 years, shown to be healthy by examination and laboratory tests, took 500 mg of ciprofloxacin every 12 h for 7 days. After the first and the last dose, blood and urine samples were taken and drug concentrations were determined by bioassay. There was a significant buildup in mean concentrations in serum from day 1 to day 7; mean peak levels (attained after 1 to 2 h) were 1.9 and 2.8 micrograms/ml, respectively. The terminal half-life was 3.5 to 4 h. About 40% of the drug was excreted into the urine during the 12-h period after dosing; minimum mean concentrations in urine were 105 micrograms/ml on day 1 and 174 micrograms/ml on day 7. Considerable amounts of ciprofloxacin were found in the feces on day 7 (185 to 2,220 micrograms/g). Marked changes in the aerobic part of the fecal flora were observed as a result of taking ciprofloxacin: coliforms were absent on day 7, and concentrations of streptococci and staphylococci were significantly reduced. There was no overgrowth by yeasts. One week later the fecal flora had returned to a state similar to that found before treatment. Anaerobes were little affected quantitatively but acquired resistance to ciprofloxacin. Side effects were mild and transient.

Entities:  

Mesh:

Substances:

Year:  1984        PMID: 6517559      PMCID: PMC180008          DOI: 10.1128/AAC.26.5.757

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN: 0066-4804            Impact factor:   5.191


  10 in total

1.  Treatment of urinary-tract infections with amphicillin. A clinical trial.

Authors:  W BRUMFITT; A PERCIVAL; M J CARTER
Journal:  Lancet       Date:  1962-01-20       Impact factor: 79.321

2.  Transport and storage of faeces for bacteriological examination.

Authors:  J S Crowther
Journal:  J Appl Bacteriol       Date:  1971-06

3.  Pharmacokinetics and tissue penetration of ciprofloxacin.

Authors:  B Crump; R Wise; J Dent
Journal:  Antimicrob Agents Chemother       Date:  1983-11       Impact factor: 5.191

4.  The pharmacokinetics and tissue penetration of norfloxacin.

Authors:  Z N Adhami; R Wise; D Weston; B Crump
Journal:  J Antimicrob Chemother       Date:  1984-01       Impact factor: 5.790

5.  Rifaprim (rifampicin plus trimethoprim): pharmacokinetics and effects on the normal flora of man.

Authors:  W Brumfitt; J M Hamilton-Miller
Journal:  Biopharm Drug Dispos       Date:  1981 Apr-Jun       Impact factor: 1.627

6.  Colonization resistance of the digestive tract: clinical consequences and implications.

Authors:  D van der Waaij
Journal:  J Antimicrob Chemother       Date:  1982-10       Impact factor: 5.790

7.  In-vitro studies with ciprofloxacin, a new 4-quinolone compound.

Authors:  D S Reeves; M J Bywater; H A Holt; L O White
Journal:  J Antimicrob Chemother       Date:  1984-04       Impact factor: 5.790

8.  Absorption, distribution, metabolic fate, and elimination of pefloxacin mesylate in mice, rats, dogs, monkeys, and humans.

Authors:  G Montay; Y Goueffon; F Roquet
Journal:  Antimicrob Agents Chemother       Date:  1984-04       Impact factor: 5.191

9.  In vitro activity of ciprofloxacin (Bay o 9867).

Authors:  R J Fass
Journal:  Antimicrob Agents Chemother       Date:  1983-10       Impact factor: 5.191

10.  In vitro activity of Bay 09867, a new quinoline derivative, compared with those of other antimicrobial agents.

Authors:  R Wise; J M Andrews; L J Edwards
Journal:  Antimicrob Agents Chemother       Date:  1983-04       Impact factor: 5.191

  10 in total
  81 in total

Review 1.  Selective decontamination in neutropenic patients.

Authors:  E Kurrle; T Schmeiser; W Kern
Journal:  Epidemiol Infect       Date:  1992-12       Impact factor: 2.451

2.  Influence of intravenously administered ciprofloxacin on aerobic intestinal microflora and fecal drug levels when administered simultaneously with sucralfate.

Authors:  W A Krueger; G Ruckdeschel; K Unertl
Journal:  Antimicrob Agents Chemother       Date:  1997-08       Impact factor: 5.191

Review 3.  The mode of action of quinolones: the paradox in activity of low and high concentrations and activity in the anaerobic environment.

Authors:  C S Lewin; I Morrissey; J T Smith
Journal:  Eur J Clin Microbiol Infect Dis       Date:  1991-04       Impact factor: 3.267

4.  Decontaminating efficacy of ciprofloxacin in an animal model.

Authors:  M L van Ogtrop; H Mattie; H F Guiot; R van Furth
Journal:  Eur J Clin Microbiol Infect Dis       Date:  1989-10       Impact factor: 3.267

Review 5.  Impact of the fluoroquinolones on gastrointestinal flora.

Authors:  V Korten; B E Murray
Journal:  Drugs       Date:  1993       Impact factor: 9.546

Review 6.  Use of the quinolones for the prophylaxis and therapy of infections in immunocompromised hosts.

Authors:  G Maschmeyer
Journal:  Drugs       Date:  1993       Impact factor: 9.546

7.  Intestinal elimination of ciprofloxacin in rabbits.

Authors:  J Ramon; S Dautrey; R Farinoti; C Carbon; E Rubinstein
Journal:  Antimicrob Agents Chemother       Date:  1994-04       Impact factor: 5.191

Review 8.  Ciprofloxacin. A review of its pharmacological profile and therapeutic use in the elderly.

Authors:  L R Wiseman; J A Balfour
Journal:  Drugs Aging       Date:  1994-02       Impact factor: 3.923

Review 9.  Quinolones in urology.

Authors:  K T Nielsen; P O Madsen
Journal:  Urol Res       Date:  1989

10.  Comparison of ceftriaxone, amikacin, and ciprofloxacin in treatment of experimental Yersinia enterocolitica O9 infection in mice.

Authors:  M Jiménez-Valera; C Gonzalez-Torres; E Moreno; A Ruiz-Bravo
Journal:  Antimicrob Agents Chemother       Date:  1998-11       Impact factor: 5.191

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.